 |
Over the past twelve years, this meeting has updated the most relevant advances in Breast Cancer. Leaders in breast cancer research and treatment have shared their knowledge with the participants, providing the latest information on state-of–the-art developments from the leading cancer centers and institutions. This conference pretends to make a comprehensive overview of this important field.
PRELIMINARY PROGRAM
| Wednesday, June 20
|
 |
9.00 am |
Introduction
L. Gianni (Milan)
H. Cortés-Funes (Madrid)
|
9.15 –10.00 am |
Opening Lecture
Assessing Prognosis for Early Breast Cancer: Clinical Versus Genetic Profiles.
Gabriel Hortobagyi (Houston)
|
10.00 – 11.00 am |
SYMPOSIUM I : (Part I) Prognostic and Risk Factors
Dissemninated Tumor Cells in Bone Marrow and Peripheral Blood as Predictors of Recurrence in Primary Breast Cancer
Wolfgang Janni (Germany)
Circulating Tumor and Endothelial Cells as Predictors of Response in Metastatic Breast Cancer
Massimo Crisfofanilli (Houston)
|
| 10.40 - 11.00 am |
Discussion
|
| 11.00 - 11.30 am |
COFFEE-BREAK
|
| 11.30 - 1.20 pm |
SYMPOSIUM I : (Part II) Prognostic and Risk Factors
The Role of MRI and Digital Mammography for Screening
David D. Dershaw (New York)
High-risk Women and Hereditary Breast Cancer: Assessment and Management
Judith E Garber (Boston)
Gene Expression Profiling for Prognosis of Breast Cancer
Marc J. van de Vijver (Amsterdam)
Gene Expression Profiling as Predictive Factor of Response to Treatment
Lajos Pusztai (Houston)
|
| 12.50 - 1.20 pm |
Discussion
|
| 1.20 – 2.30 pm |
LUNCH
|
| 2.30 - 4.20 pm |
SYMPOSIUM II : (Part I) New Strategies for Primary Treatment
Surgery After Neoadyuvant Systemic Therapy
(including the adoption of Sentinel Node Biopsy)
Elefterios P. Mamounas (Canton)
Surgery Treatment of Breast Cancer in Metastatic Disease
Seema Khan (Chicago)
Breast Reconstruction: Immediate Versus Delayed
Geoffrey Robb (Houston)
|
| 3.50 - 4.20 pm |
Discussion
|
| 4.20 – 4.40 pm |
COFFEE-BREAK
|
| 4.40 - 6.00 pm |
SYMPOSIUM II : (Part II) New Strategies for Primary Treatment
Nipple-sparing Subcutaneous Mastectomy
Jean Ives Petit (Milan)
Partial Breast Irradiation (PBI) and Intraoperative Radiotherapy
Roberto Orecchia (Milan)
An Overview of Other New Radiotherapy Technics for PBI
Felipe A. Calvo (Madrid)
|
5.40 - 6.00 pm |
Discussion
|
| |
WELCOME COCKTAIL
|
|
|
| Thursday, June 21
|
|
| 9.00 - 10.30 am |
SYMPOSIUM III: (Part I) Controversies in Clinical Practice
Trastuzumab in the Adjuvant Setting: Clinical Trials vs Clinical Practice
Edith A. Perez (Jacksonville)
Current Status of Adjuvant Endocrine Therapy for Premenopausal Patients with Primary Breast Cancer
Anthony Howell (Manchester)*
Triple-Negative (Basal-Like) Breast Cancer: A New Entity with Optimal Treatment
Lisa A. Carey (Chapel Hill)
|
10.00 – 10.30 am |
Discussion
|
10.30 – 11.00 am |
COFFEE-BREAK
|
|
| 11.00 - 12.30 pm |
SYMPOSIUM III: (Part II) Controversies in Clinical Practice
Treatment of Metastatic Breast Cancer After Current Adjuvant Approaches (Adjuvant Taxanes, Aromatase Inhibitors and Trastuzumab)
Pierfranco Conte (Modena)
Present and Future Role of Biphosphonates in Breast Cancer Treatment
Gabriel Hortobagyi (Houston)
|
12.00 – 12.30 pm |
Discussion
|
12.30 – 1.20 pm |
Proffered Papers and Posters
|
1.20 – 2.30 pm |
LUNCH
|
| 2.30 - 4.40 pm |
SYMPOSIUM IV:
Primary Systemic Therapy and Adjuvant Treatment of Breast Cancer
Standards and Future Strategies in Adjuvant Chemotherapy Treatment of Breast Cancer
Clifford Hudis (New York)
Endocrine Adjuvant Treatment for Postmenopausal Breast Cancer Patients
Eric P. Winer (Dana Farber, Boston)
Preoperative Systemic Treatment for Operable Breast Cancer:
The European Experience
Luca Gianni (Milan)
Preoperative Systemic Treatment for Operable Breast Cancer:
Biological Correlates of Response to Neoadjuvant Treatment
Gabriel Hortobagyi (Houston)
Neoadjuvant Endocrine Therapy: Clinical and Biological Issues
Ian Smith (London)
|
4.10 – 4.40 pm |
Discussion
|
|
|
| Friday, June 22
|
|
9.00 – 10.30 am |
SYMPOSIUM V:
Advances in Metastatic Disease
Chemotherapy in the Metastatic Disease: An Overview
Ian Smith (London)
Endocrine Treatment for Advanced Breast Cancer: An Overview.
Anthony Howell (Manchester)
ErbB receptor signalling and resistance to hormonal therapy in Breast Cancer
Carlos Arteaga (Nashville)
|
10.00 – 10.30 am |
Discussion
|
10.30 – 11.00 am |
COFFEE-BREAK
|
11.00 – 1.20 pm |
SYMPOSIUM VI:
Targeted Therapy: Present and Future
Epigenetics in Breast Cancer
Manel Esteller (Madrid)
Novel Targeted Therapies in Breast Cancer
José Baselga (Barcelona)
Angiogenesis Inhibition in Breast Cancer
Hernán Cortés-Funes (Madrid)
Novel Strategies for HER-2 Positive Metastatic Breast Cancer. Mechanisms and Therapeutic Options to Overcome Trastuzumab Resistance
Francisco Esteva (Houston)
Other Monoclonal Antibodies for the Treatment of Breast Cancer (Cetuximab, Omnitarg…)
José Baselga (Barcelona)
PI3kinase and resistance to EGFR/HER2 Inhibitors: implication for combinatorial therapies in Breast Cancer
Carlos Arteaga (Nashville)
|
| 1.00 – 1.30 pm |
Discussion
|
| 1.30 – 2.15 pm |
CLOSING LECTURE
The Self-Seeding Theory of Cancer and Its Clinical Implications
Larry Norton (New York)
|
|
Further Information
|
|
